Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals
Analysis of Tb-161 stock showed an increase in metal impurities over time, which could interfere with the production of Tb-161 labeled radiopharmaceuticals. The low gamma energy (48.9 keV and 74.6 keV) of Tb-161 needs to be considered in (pre)clinical applications when quantifying activity. For Tb-161 labeled pharmaceuticals, similar radiolabeling conditions as Lu-177 have been shown to be successful and highly stable.
Authors
- Yann Seimbille (ORCID: https://orcid.org/0000-0002-9736-5318)
- Erik de Blois (ORCID: https://orcid.org/0000-0002-0659-7819)
- Carolline Ntihabose
- Maryana Handula (ORCID: https://orcid.org/0000-0003-2927-5684)
- Mark Konijnenberg (ORCID: https://orcid.org/0000-0001-5895-8500)
- Debra Stuurman (ORCID: https://orcid.org/0000-0003-4923-1312)
- Corrina de Ridder (ORCID: https://orcid.org/0009-0006-2040-9032)
- Savanne Beekman
- Amber Piet
- Louise van Dalen
- Negin Eskandari
- Asude Aydogan
Institutions
- Erasmus MC (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1186/s41181-025-00390-3
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Erasmus Medisch Centrum